Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2018

Publisher Name :
Date: 30-Jan-2018
No. of pages: 97

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 4, 2, 6 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Solid Tumor, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Breast Cancer, Esophageal Cancer, Lung Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Pancreatic Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Tumor, Endometrial Cancer, Epithelial Tumor, Ewing Sarcoma, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Tumor, Peritoneal Tumor, Skin Cancer, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Thyroid Cancer.

The latest report Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Overview
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Etubics Corp
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Hummingbird Bioscience Pte Ltd
ImmunoGen Inc
MediaPharma SRL
Merrimack Pharmaceuticals Inc
Merus NV
Novartis AG
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sorrento Therapeutics Inc
Symphogen A/S
Takis Srl
XuanZhu Pharma Co Ltd
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles
AV-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-0702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-3379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elgemtumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCN-411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2849330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
huHER3-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
istiratumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-5209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lumretuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCLA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPEV-201959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patritumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poziotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seribantumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5491 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Dec 21, 2017: CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China
Nov 17, 2017: Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
Oct 30, 2017: Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
Oct 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2
Oct 17, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
Sep 28, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017
Sep 13, 2017: AVEO Oncology Announces Receipt of $0.5 million Payment from CANbridge
Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-203
Apr 03, 2017: Hummingbird Bioscience presents update on HMBD-001 at AACR in Washington DC
Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting
Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by AVEO Pharmaceuticals Inc, H1 2018
Pipeline by Celldex Therapeutics Inc, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Etubics Corp, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Pipeline by Hummingbird Bioscience Pte Ltd, H1 2018
Pipeline by ImmunoGen Inc, H1 2018
Pipeline by MediaPharma SRL, H1 2018
Pipeline by Merrimack Pharmaceuticals Inc, H1 2018
Pipeline by Merus NV, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H1 2018
Pipeline by Sorrento Therapeutics Inc, H1 2018
Pipeline by Symphogen A/S, H1 2018
Pipeline by Takis Srl, H1 2018
Pipeline by XuanZhu Pharma Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Atipamezole Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 131
    Scope of the Report: This report focuses on the Atipamezole in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Atipamezole is a synthetic alpha 2 adrenergic receptor antagonist drug, which reverses the effects of sedative and analgesic drugs such as medetomidine, xylazine, amitraz, and detomidine among others, in animals. In a......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Betamethasone Ointment Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 130
    Scope of the Report: This report focuses on the Betamethasone Ointment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Betamethasone ointment is a steroid medication that is used to treat a number of skin diseases such as dermatitis, allergic conditions, and itching. The worldwide market for Betamethasone Ointment is......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) BCG Vaccine Sales Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 128
    Scope of the Report: This report focuses on the BCG Vaccine Sales in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. BCG vaccine stands for the Bacillus Calmette Guerin vaccine intended for children and adults having high prevalence of tuberculosis (TB). The vaccine prevents from various forms of tuberculosis such as TB mening......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Baby Ddrops Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 137
    Scope of the Report: This report focuses on the Baby Ddrops in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Baby Ddrops is a purified vitamin D3 supplement for babies, specially manufactured for breastfed infants. These ddrops are tasteless and therefore don't interfere with feeding. Moreover, Health Canada recommends that ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Ayurvedic Health and Personal Care Products Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 128
    Scope of the Report: This report focuses on the Ayurvedic Health and Personal Care Products in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Better understanding of natural and alternative therapies, and adverse effects of allopathy has resulted in consumers drifting towards Ayurvedic health and personal care products.......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Preventive Asthma Drug Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 131
    Drugs for asthma attacks are bronchodilators. The products include pills, potions, inhalers and sprays. The effect is bronchiectasis, which can relieve asthma symptoms quickly and help prevent asthma attacks. This kind of medicine works well and is quite safe. But be careful not to overuse it. The main side effect is heartbeat. Commonly used are salbutamol (Salbutamol), terbutaline (Terbutaline) and so on. Scope of the Report: This report focuses on the Preventive Asthma D......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Renal Cell Carcinoma Drugs Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 129
    Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90-95% of cases.The drug is developed for fightting RCC. Scope of the Report: This report focuses on the Renal Cell Carcinoma Drugs in global market, especially in North America, Europe and Asia-Pacific, So......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sports and Fitness Nutrition Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 135
    Sports nutrition refers to the intake of nutrients from the outside world according to the characteristics of different sports items, so as to meet the needs of various nutrients due to exercise. Scope of the Report: This report focuses on the Sports and Fitness Nutrition in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) G-CSF Biosimilars Market 2018, Forecast to 2023
    Published: 19-Dec-2018        Price: US 4880 Onwards        Pages: 128
    Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000. Scope of the Report: This report focuses on the G-CSF Biosimilars in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The report provides separate comprehensive analytics for the US, Canada,......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs